Conceptos Categóricos

GEMIFLOXACINA E INFECCIONES RESPIRATORIAS EXTRAHOSPITALARIAS

GEMIFLOXACINA E INFECCIONES RESPIRATORIAS EXTRAHOSPITALARIAS

(especial para SIIC © Derechos reservados)
La gemifloxacina es un agente de máxima actividad antineumocócica que tiene importante actividad contra la mayoría de los neumococos resistentes a la ciprofloxacina y actividad pronunciada contra patógenos atípicos y gramnegativos.
blondeau9.jpg Autor:
Joseph M. Blondeau
Columnista Experto de SIIC
Artículos publicados por Joseph M. Blondeau
Coautor
Glenn Tillotson* 
Phd, Ffcp, Frsm, Replydine Inc, Louisville, EE.UU.*
Recepción del artículo
30 de Enero, 2007
Aprobación
30 de Marzo, 2007
Primera edición
8 de Octubre, 2007
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Las infecciones respiratorias bajas son una carga clínica y económica sustancial, con un costo de miles de millones de dólares anuales, a lo cual se suma otra complicación que es la resistencia creciente a los antibióticos. Esta resistencia ha comprometido la utilización de los antibióticos de uso frecuente. Se ha aprobado el uso clínico de las nuevas fluoroquinolonas como la gemifloxacina, que es caracterizada como una fluoroquinolona de doble acción con una excelente actividad contra Streptococcus pneumoniae (CIM90 0.03-0.06 μg/ml). La gemifloxacina administrada una vez al día tan sólo durante 5 días probó ser equivalente o superior a los agentes con los que se la comparó, tiene un perfil de seguridad aceptable y puede ser un agente costo-efectivo para las infecciones respiratorias bajas.

Palabras clave
infecciones extrahospitalarias del tracto respiratorio, resistencia microbiana, gemifloxacina, farmacoeconomía


Artículo completo

(castellano)
Extensión:  +/-17.73 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Lower respiratory tract infections are a substantial clinical and financial burden costing billions annually. A further complication is antimicrobial resistance among key pathogens, such as Streptococcus pneumoniae. Such resistance has compromised the use of commonly used antimicrobial compounds and influences treatment options in both the outpatient and inpatient environments. New fluoroquinolones have been introduced to meet these new demands; however, recent resistance to older compounds is a concern. Gemifloxacin is the newest to be approved for clinical use and is characterized as a potent dual-acting fluoroquinolone with excellent activity against S. pneumoniae (MIC90 0.03-0.06 μg/ml) including those demonstrating resistance to other agents including quinolones (MIC90 0.12-0.5 μg/ml). Gemifloxacin has proven equivalent to, or superior to, comparator agents in clinical trials, has an acceptable safely profile, and will likely be a cost-effective alternative for community-acquired lower respiratory tract infections including those caused by resistant pathogens.

Key words
community respiratory tract infections, antimicrobial resistance, gemifloxacin, health economics


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neumonología
Relacionadas: Atención Primaria, Farmacología, Infectología, Medicina Interna, Pediatría



Comprar este artículo
Extensión: 17.73 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Joseph M. Blondeau, Department of Clinical Microbiology, Royal University Hospital , S7N 0W8, 103 Hospital Drive, Saskatoon, Canadá
Bibliografía del artículo
1. Minino AM, Arias E, Kochanek KD, et al. Deaths: final data for 2000. Natl Vital Stat Rep 50(15), 2002.
2. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Respir Care 47(10):1184-99, 2002.
3. Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 46(Topic T1):17-24, 2000.
4. Domagala J. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 33(4):685-706, 1994.
5. Garcia I, Pascual A, Ballesta S, Joyanes P, Perea EJ. Intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 44(11):3193-5, 2000.
6. Blondeau JM, Hansen G, Borsos S, Irvine L, Blanco L. In vitro susceptibility of 4903 bacterial isolates of gemifloxcin - an advanced fluoroquinolone. Int J Antimicrob Agents 9:44-9, 2003.
7. Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveiillance Program. Clin Microbiol Infect 10:645-51, 2004.
8. Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC, SENTRY Participants Group (North America). SENTRY Antimicrobial Surveillance Program Report: Latin American and Brazilian results for 1997 through 2001. The Brazilian Journal of Infectious Diseases 8(1):25-79, 2004.
9. Lim S, Bast D, McGeer A, De Azavedo J, Low DE. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerging Infectious Diseases 9(7):833-7, 2003.
10. Pletz MWR, McGee L, Jorgenson J, et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for the clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 48:3491-7, 2004.
11. Blondeau JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opinions on Pharmacotherapy 5(5):1117-52, 2004.
12. File Jr. TM, Iannini PB. A profile of gemifloxacin, a new respiratory fluoroquinolone. Today's Therapeutic Trends 21(4):415-35, 2003.
13. Heaton VJ, Ambler J, Fisher LM. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother 44(11):3112-7, 2000.
14. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resistance Updates 2:38-55, 1999.
15. Fisher LM, Gould KA, Pan X-S, Patel S, Heaton VJ. Analysis of dual active fluoroquinolones in Streptococcus pneumoniae. J Antimicrob Chemother 52:312-6, 2003.
16. Gillespie SH, Voelker LL, Dickens A. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microbial Drug Resistance 8(2):79-84, 2002.
17. Chen DK, McGeer A, De Azavedo J, Low DE, The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 341:233-9, 1999.
18. Perez-Trallero E, Garcia-Rey C, Martin-Sanchez AM, et al. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob Agents Chemother 46(8):2665-7, 2002.
19. Oscient Pharmaceuticals. Gemifloxacin (FACTIVE), Prescribing Information. Waltham, MA, USA; 2004.
20. Seo SM, Lee SH, Choi YJ, et al. Pharmacokinetics of LB20304, a new fluoroquinolone in rats and dogs. Archives of Pharmacologic Research 19:359-67, 1996.
21. Gee T, Andrews JM, Ashby JP, Marshall G, Wise R. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. J Antimicrob Chemother 47:431-4, 2001.
22. Mandell LA, Bartlett JG, Dowell SF, File Jr. TM, Musher DM. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37(11):1405-33, 2003.
23. Balter MS, La Forge J, Low DE, Mandell LA, Grossman RF, Chronic Bronchitis Working Group. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 10(Suppl. B):3B-32B, 2003.
24. Ball P, File Jr. TM, Twynholm M, Henkel T, 061 Study Group. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents 18:19-27, 2001.
25. Lode H, File Jr. TM, Mandell LA, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 24(11):1915-36, 2002.
26. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44(1):79-86, 2007.
27. File Jr. TM, Schlemmer B, Garau J, Cupo M, Young C, 049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 48:67-74, 2001.
28. Leophonte P, File Jr. TM, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Resp Med 98:708-20, 2004.
29. Wilson R, Schentag JJ, Ball P, Mandell LA, 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 24(4):639-52, 2002.
30. Sethi S, Fogarty C, Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Resp Med 98(8):697-707, 2004.
31. File Jr. TM, Sclemmer B, Garau J, et al. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. J Chemother 12:314-25, 2000.
32. Ball P, Wilson R, Mandell LA, Brown J, Henkel T, 069 Clinical Study Group. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin. J Chemother 13(3):288-98, 2001.
33. Wilson R, Langan C, Ball P, Bateman K, Pypstra R, Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Resp Med 97:242-9, 2003.
34. Ferguson BJ, Anon J, Poole MD, et al. Short treatment durations for acute bacterial rhinosinusitis: five days of gemifloxacin versus 7 days of gemifloxacin. Otolaryngol Head Neck Surg 127(1):1-6, 2002.
35. Halpern MT, Palmer CS, Zodet M, Kirsch J. Cost-effectiveness of gemifloxacin: results from the GLOBE Study. Am J Health Syst Pharm 59(14):1357-65, 2002.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
-->